Overall, our research unveils an uncharted axis involving MUFA, HMGB1, and PD-L1 in NSCLC by illuminating the intricate lipid metabolism network, immune regulation, and potential therapeutic targets within this challenging disease. This evidence concerns the gene HMGB1 and non-small cell lung carcinoma.